Intelligence
Ventures
Mental
Wellness
A safe, clean, and healthful world is both our birthright and our responsibility.
Ei.Ventures is building a platform around the use of natural medicines and their ability to support the symbiosis of happy humans and a healthy planet.
Our ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic.
We seek to provide a free resource to the individual that will provide critical data for further academic understanding of psychoactive compounds.
As the pace of decriminalization continues to snowball, we watch with interest as the legal backdrop and DEA scheduling status remains on the political agenda. In markets that allow self therapy, we anticipate being able to provide a suite of products.
American adults suffer from a mental illness
The increase in the prevalence of anxiety & depression worldwide in the last 2 years
The increase in antidepressant prescription rate in the last two decades
People over the age of 12are prescribed antidepressants
The percent of US adults that say they have confidence in medical scientists to act in the best interest of the public (that is a 40% decrease in just two years)
Compound Annual Growth Rate (CAGR) of the complementary & alternative medicine market, 2021-2030
Complimentary & alternative medicine market size, 2020-2030, USD billion - Pew Research
- 80% of trial participants at 6-month stage following treatment were showing significantly reduced symptoms of anxiety and depression.
- 80% endorsing moderately or greater increased well-being/life satisfaction.
- Estimated that only 33% of depression patients benefit from currently available treatment options.
- 80% of participants were abstinent in the 6 month follow-up, and 73% were biologically confirmed to have quit smoking (Chantix – best-in-class – currently delivers a 35% quit rate).
- 12 month follow-up showed 67% remained abstinent. In 2017, an additional follow-up confirmed that 60% remained abstinent.
- 300 million global sufferers.
- 76% of MDMA-assisted psychotherapy patients were deemed to be successfully treated 12 months after therapy with similar results being seen with psilocybin.
Ei.Ventures, Inc. (“Ei” or the “Company”) has entered into a non-binding letter of intent dated March 25, 2024 (the “Letter of Intent”) with Orthogonal Global Group Inc. (formerly known as Web3 Ventures Inc.) (“OGG”), a global accelerator and public investment platform currently listed on the Canadian Securities Exchange (CSE: OGG), Frankfurt Stock Exchange (FSE: KZ2) and OTC Pink (OTC Pink: OGGIF), focused on furthering initiatives in the wellness, healthcare, AI, blockchain tokenization, deep-tech and gaming spaces, and Orthogonal Thinker, Inc., an accelerator focused on health, wellness, technology, deep-tech and tokenization (“Thinker”), to seize on the convergence of these cutting-edge industries and technologies, and to give access to these otherwise private opportunities on a senior exchange in the North American public capital markets.
David Nikzad, CEO of Ei states “We believe this is the right opportunity to provide liquidity to our shareholders through a merger or combination with OGG and Thinker, and a path forward to determine which public exchange is best for a combined company, especially after the difficult headwinds the last couple of years experienced by companies engaged in psychedelics, the metaverse and blockchain projects and other cutting-edge healing modalities looking to access the public markets.” Without regulatory relief on a federal level for cutting-edge industries like psychedelics and blockchain/crypto initiatives such as the metaverse, the U.S. public capital markets have been difficult to navigate and access for emerging companies. But with the wider adoption of AI, AR/VR, and crypto-based initiatives and products (e.g., BTC ETFs), the convergence of these industries presents an opportunity to expand Ei’s “play to heal” presence in the metaverse (blockchain/NFTs), to further work on technology platforms to give access to healings, the Company’s products and offerings for integration of psychedelic experiences for most of the world’s population which doesn’t have regular access to medical clinics or trained providers engaged in these healings. Given the combined holdings and focus of both OGG and Thinker, as well as shared values and common ownership and control among the companies, Ei entered into the Letter of Intent to lay-out a framework to move forward towards accessing the public capital markets.
The Letter of Intent anticipates the companies will enter into a definitive agreement with terms and conditions of a merger or business combination on or before September 30, 2024, including, but not limited to approved third-party valuations of Ei and Thinker, any regulatory approvals for the merger or business combination required of OGG, approval by the respective board of directors and to the extent required, by the respective shareholders, and an agreed upon path forward to list on a senior exchange in North America or to remain on the CSE and FSE as a combined company, subject to CSE and FSE regulatory approval, among other conditions.
Until a Definitive Agreement is reached, OGG has not circulated a press release or made any filing with the CSE or FSE regarding the Letter of Intent.